FR2768342A1 - Anti-hemorrhoidal cream for topical application - Google Patents

Anti-hemorrhoidal cream for topical application Download PDF

Info

Publication number
FR2768342A1
FR2768342A1 FR9711355A FR9711355A FR2768342A1 FR 2768342 A1 FR2768342 A1 FR 2768342A1 FR 9711355 A FR9711355 A FR 9711355A FR 9711355 A FR9711355 A FR 9711355A FR 2768342 A1 FR2768342 A1 FR 2768342A1
Authority
FR
France
Prior art keywords
glycerin
power
astringent
acid
sodium citrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR9711355A
Other languages
French (fr)
Other versions
FR2768342B3 (en
Inventor
Jean Louis Masson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR9711355A priority Critical patent/FR2768342B3/en
Publication of FR2768342A1 publication Critical patent/FR2768342A1/en
Application granted granted Critical
Publication of FR2768342B3 publication Critical patent/FR2768342B3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

An anti-hemorrhoidal cream containing tannic acid, potassium alum, sodium citrate and glycerin.

Description

La présente invention concerne une crème curative aux propriétés scléro-rétractiles et fibrosantes pour application locale sur les hémorroïdes.The present invention relates to a curative cream with sclero-retractile and fibrosing properties for local application on hemorrhoids.

Jus qu'à ce jour les crèmes et traitements locaux antihémorroïdaires sont destinés, soit à calmer les crises de fluxion (traitements d'urgence, paliatifs), soit à améliorer divers facteurs de la circulation sanguine (traitements de fond, fonctionnels), mais n'ont jamais apporté une solution curative au sens anatomo-pathologique du terme, à la maladie hémorroïdaire. Until now, local anti-hemorrhoidal creams and treatments are intended either to calm seizures (emergency, palliative treatments) or to improve various factors of blood circulation (basic, functional treatments), but n have never provided a curative solution in the anatomo-pathological sense of the term, to hemorrhoidal disease.

Cette crème a pour effets, non seulement le traitement d'urgence des crises de fluxion, mais en traitement de fond la cure, c'est à dire la guérison à long terme des hémorroïdes. This cream has the effects, not only of the emergency treatment of seizures, but as a basic treatment, that is to say, the long-term healing of hemorrhoids.

Elle est constituée de quatre principes actifs qui jouent le rôle d'agents astringeants et fibrosants et dont l'association permet l'efficaåté par interpotentialisation des effets. Ces principes actifs comportent: - l'acide tanique qui est du tanin à l'ether ou acide gallotannique, extrait de la noix de Galle (glucoside complexe) au fort pouvoir astringeant - l'alun de potassium qui est un sel de potasse en poudre soluble dans le glycérol au pouvoir astringeant et caustique selon le dosage. It is made up of four active ingredients which play the role of astringent and fibrosing agents and whose association allows the effectiveness by interpotentialisation of the effects. These active ingredients include: - tannic acid which is ether tannin or gallotannic acid, extracted from gall nut (complex glucoside) with strong astringent power - potassium alum which is a powdered potassium salt soluble in glycerol with astringent and caustic power depending on the dosage.

- le citrate de sodium qui est du citrate trisodique hydraté (acide citrique saturé au bicarbonate de sodium) au pouvoir astringeant et antiseptique.- sodium citrate which is hydrated trisodium citrate (citric acid saturated with sodium bicarbonate) with astringent and antiseptic power.

- la glycérine ou glycérol à 3% d'eau qui est un trialcool, au pouvoir irritant muqueux. En dehors des principes actifs (acide tanique, alun de potassium, citrate de sodium, glycérine) la formule comprend une petite dose d'anesthésique local (chlorhydrate de procaïne) un durcisseur (aerosil) et un excipient en émulsion (cétaline). Elle est composée par la formule suivante à considérer comme une formule "moyenne". Les dosages de chaque élément sont donnés en poids correspondant à la présentation du produit en tube de 20 gr., ainsi qu'en pourcentage pour en faciliter la lecture.- glycerin or glycerol at 3% water which is a tri-alcohol, with mucosal irritant power. Apart from the active ingredients (tanic acid, potassium alum, sodium citrate, glycerin) the formula includes a small dose of local anesthetic (procaine hydrochloride) a hardener (aerosil) and an emulsion excipient (ketaline). It is composed by the following formula to be considered as an "average" formula. The dosages of each element are given in weight corresponding to the presentation of the product in a 20 gr tube, as well as in percentage to facilitate reading.

Formule dosages "moyenne" - Acide tanique 4.gr . ..... soit 20%
(tanin à I'ether ou extrait du gallnut) - Alun de potassium 0,30gr ..... ..... soit 1,5% - citrate de sodium 0,30gr .......... soit 1,5% - glycérine 0,20gr ........ soit 1% - chlorhydrate de procaine 0,20gr . soit 1% - aerosil (poudre de silice) 0,20gr .. .. soit 1% -cétaline excipient Q.S.P. 20gr. . soit 74% (émulsion de cétazal)
Il est possible de s'écarter en dosages supérieurs ou inférieurs de cette formule moyenne dans une fourchette de 0,10% à 50si de la formule totale pour chaque élément.
Dosage formula "medium" - Tannic acid 4.gr. ..... or 20%
(ether tannin or gallnut extract) - Potassium alum 0.30gr ..... ..... or 1.5% - sodium citrate 0.30gr .......... either 1.5% - glycerin 0.20gr ........ or 1% - procaine hydrochloride 0.20gr. either 1% - aerosil (silica powder) 0.20gr .. .. or 1% - ketaline excipient QSP 20gr. . or 74% (cetazal emulsion)
It is possible to deviate in higher or lower dosages from this average formula in a range of 0.10% to 50si of the total formula for each element.

Le produit est présenté sous forme de "crème" de type émulsion en tube de 20 gr. sur lequel on peut remplacer le bouchon par une canule applicatrice mousse destinée à l'injection dans le canal anal. The product is presented in the form of an "emulsion" type cream in a 20 gr tube. on which the plug can be replaced by a foam applicator cannula intended for injection into the anal canal.

Le produit agit par scléro-rétraction à la fois vasculaire et muqueuse, permettant d'obtenir à terme, une fibrose cicatricielle souple. L'effet obtenu est une rétraction des paquets hémorroidaires veineux ainsi que des anastomoses artério-veineuses après une phase d e vasoconstriction entretenue par application fréquente et régulière de la crème. L'effet inflammatoire est relativement faible voire négligeable au moment de chaque application car l'action bactériostatique est importante. L'action sur le muscle lisse (sphincter) est nulle et il n'y a donc pas d'effet sphinctérien indésirable. L'action, y compris à long terme du médicament, est donc curative en ce qui concerne la pathologie hémorroïdaire (hémorroïdes anatomopathologiques et fluxions).The product acts by both vascular and mucosal sclerotherapy, making it possible to obtain flexible scar fibrosis over time. The effect obtained is a retraction of the venous hemorrhoidal packets as well as arteriovenous anastomoses after a phase of vasoconstriction maintained by frequent and regular application of the cream. The inflammatory effect is relatively weak or even negligible at the time of each application because the bacteriostatic action is important. The action on the smooth muscle (sphincter) is zero and there is therefore no undesirable sphincter effect. The action, including long-term of the drug, is therefore curative with regard to hemorrhoidal pathology (anatomopathological hemorrhoids and fluxions).

Les applications sont à pratiquer 2 à 3 fois par jour en phase de fluxion, puis une application matin et soir pendant 3 semaines, puis pour atteindre l'effet curatif une fois par jour pendant 3 mois. Le produit devra être appliqué après avoir lavé l'anus à l'eau pure et ne doit pas être appliqué avant d'aller à la selle.  The applications are to be carried out 2 to 3 times a day in the phase of flux, then an application morning and evening for 3 weeks, then to reach the curative effect once a day for 3 months. The product should be applied after washing the anus with pure water and should not be applied before having a bowel movement.

Claims (3)

RevendicationsClaims 1) Crème anti-hémorroïdaire curative aux propriétés sclérorétractiles et fibrosantes pour application locale sur les hémorroïdes caractérisée par l'utilisation dans sa formule de 4 principes actifs (acide tanique, alun de potassium, citrate de sodium, glycérine), un anesthésique local (chlorhydrate de procaïne), un durcisseur (aerosil) et un excipient en émulsion (cétaline) 1) Curative anti-hemorrhoidal cream with scleroretractile and fibrosing properties for local application on hemorrhoids characterized by the use in its formula of 4 active principles (tanic acid, potassium alum, sodium citrate, glycerin), a local anesthetic (hydrochloride procaine), a hardener (aerosil) and an emulsion excipient (cetaline) 2) Crème selon la revendication N 1, dont les principes actifs sont caractérisés de la manière suivante: - l'acide tanique est du tanin à l'ether ou acide gallotannique, extrait de la noix de Galle (glucoside complexe) au fort pouvoir astringeant - l'alun de potassium est un sel de potasse en poudre soluble dans le glycérol au pouvoir astringeant et caustique selon le dosage. 2) Cream according to claim N 1, the active principles of which are characterized as follows: - tannic acid is tannin with ether or gallotannic acid, extracted from gall nut (complex glucoside) with strong astringent power - potassium alum is a powdered potassium salt soluble in glycerol with astringent and caustic power depending on the dosage. - le citrate de sodium est du citrate trisodique hydraté (acide citrique saturé au bicarbonate de sodium) au pouvoir astringeant et antiseptique.- sodium citrate is hydrated trisodium citrate (citric acid saturated with sodium bicarbonate) with astringent and antiseptic power. - la glycérine ou glycérol à 3% d'eau est un trialcool, au pouvoir irritant muqueux.- Glycerin or glycerol at 3% water is a tri-alcohol, with mucosal irritant power. 3) Crème selon les revendications N 1 et N 2, caractérisée par 3) Cream according to claims N 1 and N 2, characterized by la composition suivante: - Acide tanique 4.gr ................ soit 20% the following composition: - Tannic acid 4.gr ................ or 20% (tanin à l'ether ou extrait du gallnut) - Alun de potassium 0,30gr. .... .... soit 1,5% - citrate de sodium 0,30gr ........... soit 1,5% - glycérine 0,20gr ..... ..... soit 1% - chlorhydrate de procaïne 0,20gr .. .. soit 1% - aerosil (poudre de silice) 0,20gr. .... .... soit 1% -cétaline excipient Q.S.P. 20gr. ........... soit 74% (émulsion de cétazal) (ether tannin or gallnut extract) - Potassium alum 0.30gr. .... .... either 1.5% - sodium citrate 0.30gr ........... or 1.5% - glycerin 0.20gr ..... .... either 1% - procaine hydrochloride 0.20gr .. .. or 1% - aerosil (silica powder) 0.20gr. .... .... i.e. 1% - cetaline excipient Q.S.P. 20gr. ........... or 74% (cetazal emulsion) Il est possible de s'écarter en dosages supérieurs ou inférieurs de cette formule moyenne dans une fourchette de 0,10% à 50% de la formule totale pour chaque élément. It is possible to deviate in higher or lower dosages from this average formula within a range of 0.10% to 50% of the total formula for each element.
FR9711355A 1997-09-12 1997-09-12 CURATIVE CREAM WITH SCLERO-RETRACTILE AND FIBROSIVE PROPERTIES ON HEMORROIDS Expired - Lifetime FR2768342B3 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR9711355A FR2768342B3 (en) 1997-09-12 1997-09-12 CURATIVE CREAM WITH SCLERO-RETRACTILE AND FIBROSIVE PROPERTIES ON HEMORROIDS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9711355A FR2768342B3 (en) 1997-09-12 1997-09-12 CURATIVE CREAM WITH SCLERO-RETRACTILE AND FIBROSIVE PROPERTIES ON HEMORROIDS

Publications (2)

Publication Number Publication Date
FR2768342A1 true FR2768342A1 (en) 1999-03-19
FR2768342B3 FR2768342B3 (en) 1999-12-03

Family

ID=9511012

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9711355A Expired - Lifetime FR2768342B3 (en) 1997-09-12 1997-09-12 CURATIVE CREAM WITH SCLERO-RETRACTILE AND FIBROSIVE PROPERTIES ON HEMORROIDS

Country Status (1)

Country Link
FR (1) FR2768342B3 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014194966A1 (en) * 2013-06-07 2014-12-11 Shrivastava Rémi Composition for topical application comprising glycerol and tannins
WO2021137743A1 (en) * 2020-01-01 2021-07-08 Saudi Pharmaceutical Industries & Medical Appliances Corporation Spimaco Addwaeih Unique herbal combination for the treatment of anal fissures and wounds in pharmaceutical dosage form

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014194966A1 (en) * 2013-06-07 2014-12-11 Shrivastava Rémi Composition for topical application comprising glycerol and tannins
CN105377300A (en) * 2013-06-07 2016-03-02 雷米·什里瓦斯塔瓦 Composition for topical application comprising glycerol and tannins
US9597298B2 (en) 2013-06-07 2017-03-21 Remi Shrivastava Composition for topical application comprising glycerol and tannins
US10335364B2 (en) 2013-06-07 2019-07-02 Remi Shrivastava Composition for topical application comprising glycerol and tannins
WO2021137743A1 (en) * 2020-01-01 2021-07-08 Saudi Pharmaceutical Industries & Medical Appliances Corporation Spimaco Addwaeih Unique herbal combination for the treatment of anal fissures and wounds in pharmaceutical dosage form

Also Published As

Publication number Publication date
FR2768342B3 (en) 1999-12-03

Similar Documents

Publication Publication Date Title
JP4745608B2 (en) Skin treatment using phosphoric acid derivatives of electron transfer agents
ES2420516T3 (en) Topical compositions and use thereof for the treatment of conditions related to the epithelium
IT8024370A1 (en) THERAPEUTIC COMPOSITION OF DIMETHYL SULPHOXIDE AND PROCEDURES FOR ITS USE
RU2004122429A (en) GEL CONTAINING AT LEAST ONE RETINOID AND BENZOIL PEROXIDE
JPH06503567A (en) Treatment of local infections
CA2764577C (en) Method of preventing renal disease and treating symptoms thereof
FR2788695A1 (en) Cosmetic composition for use as a shower gel, bathing product, foaming gel for the face comprises menthol and menthyl lactate
JP5765744B2 (en) Preventive or therapeutic agent for atopic dermatitis, and external preparation
FR3061434A1 (en) COSMETIC COMPOSITION COMPRISING AN ASSOCIATION OF PONGAMIA OIL AND PENTYLENE GLYCOL 4-T-BUTYLCYCLOHEXANOL FOR CONTROLLING ROSACEA
FR2694194A1 (en) Hydrating gel, medicament and cosmetic composition containing it, process for the preparation of said gel.
RU2564944C1 (en) Ointment with metronidazole, bee moth larvae extract and anaesthesine for integrated treatment of inflammatory periodontal diseases
FR2768342A1 (en) Anti-hemorrhoidal cream for topical application
FR2646603A1 (en) CLEANING COMPOSITION
JP2023038290A (en) Leucine derivatives, compositions comprising the same, and applications thereof
EP1194136A1 (en) Non-solid composition for local application
FR2463617A1 (en) NOVEL SLIMMING COMPOSITIONS BASED ON MUCOPOLYSACCHARIDES AND ESCINE
EP0519777A1 (en) Galenical forms based on fresh or dried plants
JPH04334321A (en) Preventive for dermatic inflammation
RU2467738C1 (en) Dental ointment with chlorhexidine and aminocapronic acid for integrated treatment of inflammatory periodontal diseases
FR2504009A1 (en) Topical compsns. contg. arnica extract - together with camphor, menthol and surfactant for topical treatment of inflammations and infections
JP2757188B2 (en) Anti-itch agent
KR20210057691A (en) A composition for prevention, improvement or treatment of skin diseases containing a Ophiopogonin-D
US20210030698A1 (en) Gel containing zerumbone from bitter ginger (zingiber zerumbet) for curative treatment of diabetic ulcers
EP1628672A2 (en) Composition and use of pure iodine dissolved in essential oil of melaleuca alternifolia and/or melaleuca quinquenervia
JP2002212048A (en) Skin bleaching cosmetic containing natural black component extracted from muscovado